Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
NCT05101070Phase 2Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2022
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of S-531011 in solid tumor, colorectal cancer (CRC), sponsored by Shionogi & Co., Ltd.. Started May 2022; status: recruiting.
02
Drugs
S-531011
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05101070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101070.